Skip to main content

OPCIONES TERAPEUTICAS DE LA CICLOOXIGENASA 2 EN LA ENFERMEDAD DEL HIGADO GRASO NO ALCOHOLICO: UNA APROXIMACION A LA NANOTECNOLOGIA

PID2019-108977RB-I00

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Role of cyclooxygenase 2 (COX-2) in liver mitochondrial function after ischemia-reperfusion injury

  • Fuertes-Agudo, Marina
  • Cucarella, Carme
  • Brea, Rocío
  • Boscá, Lisardo
  • Martín-Sanz, Paloma
  • Casado, Marta
Póster presentado al: Liver Meeting AASLD 2021: American Association fort eh Study of Liver Diseases. (Anaheim, CA, USA and virtual), 12-15 de novembre 2021 Abstract: 470, pag. 293A, In this work, we analyzed different aspects in order to characterize the impact of COX-2 in mitochondrial function after IRI., This work was supported by SAF2016-75004-R (MINECO, Spain) and PID2019-108977RB-I00 (MICINN, Spain), CIBERehd (ISCIII, Spain). M F-A. is recipient of FPI fellowship from MINECO (BES-2017-081928), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Liver spheroids: a robust human in vitro system for testing the therapeutic options of cyclooxygenase 2 in NAFLD/NASH

  • Huete, Javier
  • Fuertes-Agudo, Marina
  • Brea, Rocío
  • Luque-Tévar, María
  • Cucarella, Carme
  • Martín-Sanz, Paloma
  • Casado, Marta
Trabajo presentado en las XV Jornadas CIBER Enfermedades Hepáticas y Digestivas: Jornades científiques del CIBERehd, celebradas en modalidad virtual y de forma presencial en Barcelona (España) del 08 al 09 de noviembre de 2021., Cyclooxygenase (COX) is a key enzyme in the biosynthesis of prostanoids. Prostaglandins are involved in multiple homeostatic processes, as well as playing an important role in the onset of inflammation. COX-2 is an isoform that is expressed and induced by different stimuli in various tissues and cell types; however, in liver, COX-2 expression is restricted to those situations where proliferation and dedifferentiation occur (1). Our previous results have shown that COX-2 expression in hepatocytes protects against hyperglycemia-induced liver damage, peripheral insulin resistance and adiposity in mice fed a high-fat diet (2), and also protects against experimental non-alcoholic steatohepatitis and fibrosis (3)., This work was supported by SAF2016-75004-R and PID2019-108977RB-I00 (MINECO, Spain) and CIBERehd (ISCIII, Spain). M F-A. and M L-T are recipient of FPI fellowship from MINECO (BES-2017-081928 and PRE2020-094885, respectively). We thank FEDER for financial support.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Liver spheroids: a robust human in vitro system for testing the therapeutic options of cyclooxygenase 2 in NAFLD/NASH

  • Fuertes-Agudo, Marina
  • Brea, Rocío
  • Luque-Tévar, María
  • Cucarella, Carme
  • Martín-Sanz, Paloma
  • Casado, Marta
Trabajo presentado en el FASEB Science Research Conference: The Liver Biology Conference: Fundamental Mechanisms and Translational Applications,, [Background]: NAFLD is the most prevalent chronic liver disease in the world and is considered the hepatic manifestation of metabolic syndrome. It begins with an accumulation of fat in the liver, which can lead to cellular damage and inflammation (NASH) and, if unaddressed, progresses to liver fibrosis, where parenchymal tissue is replaced by extracellular matrix. Cyclooxygenase (COX) is a key regulatory step in the biosynthesis of prostanoids. The COX-2 isoform is expressed and induced by different stimuli in various tissues and cell types; however, in liver, COX-2 expression is restricted to those situations in which proliferation or dedifferentiation occur (1). Our previous results revealed that COX-2 expression in hepatocytes protects against hyperglycemia-induced liver damage and against peripheral insulin resistance and adiposity in mice subjected to a high-fat diet (2). Furthermore, COX-2 expression in hepatocytes protects against experimental nonalcoholic steatohepatitis and fibrosis in mice (3). [Aims]: Since our previous results are performed in mice, we wanted to bridge from animal models to a more translational research, close to human. Therefore, we wanted to establish an in vitro model based on 3D human cell culture to evaluate the role of COX-2, specifically the role of prostaglandins, in a human model of NAFLD/NASH. [Methods]: To analyze the role of COX-2 in steatosis and fibrosis, we established a 3D spheroid culture composed of HepG2 and LX-2 cells. These spheroids were treated with palmitic acid and TGF¿ to induce NAFLD/NASH and fibrosis, respectively. They were then treated with PGE2 to evaluate their effect in this model. [Results]: In summary, our results demonstrate that PGE2 treatment reduces lipid levels after fatty acid exposure. Moreover, it reduces fatty acid-induced cell damage and insulin resistance. Furthermore, PGE2 slows fibrotic progression by decreasing stellate cells activation after TGF¿ stimulation. Conclusions: These preliminary results indicate that a therapeutic strategy for the treatment of NAFLD/NASH may be COX-2-derived prostaglandin therapy., This work was supported by SAF2016-75004-R and PID2019-108977RB-I00 (MINECO, Spain) and CIBERehd (ISCIII, Spain). M F-A. and M L-T are recipient of FPI fellowship from MINECO (BES-2017-081928 and PRE2020-094885, respectively). We thank FEDER for financial support.